Categoria: Articoli in lingua originale

August 2009 – In findings that add to the prospects of regenerating insulin-producing cells in people with type 1 diabetes, researchers in Europe — co-funded by the Juvenile Diabetes Research Foundation — have shown that insulin-producing beta cells can be derived from non-insulin-producing cells in the pancreas. In results of

In patients with Type 1 diabetes, the presence and severity of chronic kidney disease predicts all-cause mortality, according to a new report.  Mortality among Type 1 diabetics in Finland is 3 to 4 times that in the general population, the authors explain, but not all patients with Type 1 diabetes

Metformin, one of the most widely used diabetes drugs, may offer patients the added benefit of lowering their odds for pancreatic cancer by 62%, a new study shows.  But the study had a downside: other common treatments, including the use of insulin or insulin-releasing medications such as sulfonylureas, seemed to

In findings that add to the prospects of regenerating insulin-producing cells in people with type 1 diabetes, researchers in Europe — co-funded by the Juvenile Diabetes Research Foundation — have shown that insulin-producing beta cells can be derived from non-insulin-producing cells in the pancreas. In results of a study published

FDA is aware of four recently-published observational studies that looked at the use of Lantus (insulin glargine) and possible risk for cancer in patients with diabetes. Three of the four studies suggest an increased risk for cancer associated with use of Lantus.  See http://www.diabetologia-journal.org/cancer.html. Based on the currently available data,

JDRF-funded researchers have discovered further evidence that regulatory T cells are a promising cell-based therapy for type 1 diabetes. Jeffrey Bluestone, Ph.D., and colleagues from the Diabetes Center at the University of California, San Francisco have shown that regulatory T cells can be isolated from people with type 1 diabetes,